We assessed the value of fusion 18 Using the mean 18 F-choline target-to-background ratio (TBR), the addition of 18 F-choline to mpMRI significantly improved the prediction of Gleason ≥ 3+4 cancers over mpMRI alone (AUC = 0.92; p<0.001). Conclusions: Fusion PET/MRI-TRUS image registration for targeted prostate biopsies is clinically feasible and accurate. The addition of 18 F-choline PET to mpMRI improves identification of significant prostate cancer.
INTRODUCTION
Several studies have reported superior identification of significant prostate cancer using imageguided (targeted) prostate biopsies compared to non-targeted standard biopsies. Generally, these approaches utilize multi-parametric (mpMRI) as the primary targeting tool or target following fusion with 3-dimensional endorectal ultrasound (1, 2) . Both methodologies rely on the diagnostic advantages of mpMRI to reliably identify and risk-stratify clinically significant prostate cancer. However, mpMRI is not perfect; there is a need to better risk-stratify intermediate and low-risk targets identified on mpMRI. One potential area of opportunity lies with PET/MRI, in which the multi-parametric advantages of MRI can be combined with the functional advantages of PET. The introduction of hybrid PET/MRI scanners promises optimal spatial and temporal registration of PET and MRI data with the added benefit of functional imaging.
It has been shown that increased choline uptake is associated with significant primary prostate cancer (3) and cancers with elevated tumor cell proliferation markers (MIB-1/Ki67) (4) . Although choline uptake is not specific for prostate cancer (i.e., it can be seen in benign prostatic hyperplasia (BPH) (3)), there is evidence that fusion PET/MRI using a derived parameter (quotient of 11 C-choline lesion standardized uptake value (SUV) and apparent diffusion coefficient (ADC) obtained from diffusion-weighted MRI) improves image-contrast for the identification of Gleason ≥ 7 disease (5). This superior tissue contrast enhances the association of impeded diffusion with intermediate and high-risk cancers (6) (7) (8) (9) (10) .
Here we present an interim analysis of the first registered ongoing prospective diagnostic trial of fusion PET/MRI for targeted prostate biopsies. Imaging includes 18 F-choline fusion PET/MRI for the diagnosis of prostate cancer using targeted and standard biopsies. The purpose of our study is to determine whether the addition of 18 F-choline PET/CT augments the identification of clinically-significant prostate cancer over MRI alone.
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MATERIALS AND METHODS

Patient Population
We report on the first 36 consecutive subjects of this Health Insurance Portability and Accountability Act compliant registered ongoing prospective trial (Clinicaltrials.gov identifier: NCT01751737). The study was conducted in men with rising PSA values with (n = 15) or without (n = 21) biopsy-proven, untreated localized adenocarcinoma of the prostate scheduled to undergo a clinically indicated prostate biopsy. Exclusion criteria were as follows: prostate biopsy performed less than 6 weeks before imaging, previous external radiation treatment of the pelvis, prior malignancy other than basal or squamous cell skin cancers, active inflammatory bowel disease, and acute prostatitis. The institutional ethics committee approved this protocol. Written informed consent was obtained.
Study participants, 64 ± 5.3 years of age (range 56 -77), had 1.7 ± 1.4 (range 0 -6) biopsy procedures prior to entering the trial (Supplemental Table 1 ). The mean time interval from the last biopsy to study enrollment was 21.2 ± 17.7 months, within a range of 3 to 96 months. Prior biopsy results included 12 subjects with Gleason 3+3 prostate cancer, 2 with low-volume Gleason 3+4 prostate cancer, and 17 with no prior prostate cancer diagnosis. In all cases (including prior outside biopsies), tissue obtained was reviewed by the study pathologist blinded to the imaging results. Four subjects did not have a prior biopsy. PSA levels at study entry ranged from 3.0 to 153 ng/mL (mean: 13.8 ± 24.7).
Multi-sequence MRI
In vivo MRI pelvis examinations of the prostate gland with and without contrast material were performed prior to biopsy. All imaging was performed on the same 3T MR unit (Ingenia, Philips Healthcare, Andover, MA, U.S.) without an endorectal coil using a 16- (12, 13) . While PI-RADS version 1 was available at the time, it was not sufficiently validated and not generally accepted locally or nationally.
18
F-choline PET/CT
18 F-choline was synthesized as described in supplemental methods (14) . MRI and 18 
Image Registration Tasks and Target Selection
PET data were registered onto 3D T2w MR using commercially available software (MIM Maestro, Cleveland, Ohio, U.S.). Registration of in vivo modalities (PET/CT onto T2w MRI) was generally achieved without difficulties. The result of rigid registrations was visually assessed using pelvic bones as landmarks. MRI was performed without endorectal coil and patients were by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from asked to fully empty their bladder for scanning, which limited deformation of the prostate. If rectal content or bladder filling shifted the position of the prostate, a constrained intensity-based, free-form deformable registration was added to register the prostate on MRI and PET (16) . Such registration was possible using the outline of the bladder base and internal prostatic structures (such as BPH nodules) identified on both imaging as landmarks.
Lesion borders were drawn by the radiologists on a T2w 3D sequence to define one or more volume(s) of interest (VOI) as biopsy target(s). This target VOI was mirrored to the contralateral side of the prostate to create a background VOI for later data analysis. In one case (identifier (ID) 36 [Supplemental Table 1 ]), the target was located in the midline near the base, requiring a caudal (rather than lateral) shift in the mirrored background VOI to a similar anterior location.
Target T2w MRI and Real-time 3D TRUS Registration
The biopsy procedure was performed 16 ± 10 (range 3 -56) days after PET/CT imaging using a 3D ultrasound system equipped with a magnetic navigation option (General Electric Logiq E9, Aurora, OH, U.S.). The ultrasound tranducer was inserted into the rectum under local anesthesia. TRUS-MRI registration requires technical skill and additional time (~10-15 minutes) for suitable targeting. The 3D T2w MR sequence with embedded target information was loaded into the ultrasound system and rigidly fused with real-time 3D ultrasound. We used a semiautomated 3-point registration system in which at least 3 definable intra-prostatic structures (e.g., cysts, BPH nodules) were identified and marked on both MR and endorectal ultrasound images in real-time image space at the time of biopsy to permit rigid registration to occur. We subjectively rated the registration quality (0 = no registration, 1 = poor, 2 = adequate, 3 = excellent). Adequate or better registration was achieved in the majority (28 of 36) of cases. If registration attempts failed, a cognitive registration was attempted by targeting a lesion on ultrasound that appeared to be in the vicinity of the MRI-identified lesion (17, 18) . After targeted biopsies, by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from standard (systematic 12-core) prostate biopsies using an 18-gauge biopsy needle loaded in a spring-action biopsy device were obtained.
Pathological Evaluation
Biopsy samples and whole mount sections after prostatectomy were processed for routine histological assessment (hematoxylin/eosin stain) using the paraffin embedding process and 3 µm sections. Each tumor focus was assigned a primary and secondary Gleason grade and staged according to American Joint Committee on Cancer guidelines (19) . Final pathology was defined as the highest Gleason score of any cancer detected (per side of the prostate gland) from any (reviewed) tissue (prior biopsy, standard and targeted biopsy, or -if available -prostatectomy specimen as gold standard). For this study, significant prostate cancer was defined conservatively as any Gleason ≥ 3+4 cancer, including low-volume disease (20) .
Registration of T2w Ex Vivo Prostate Specimen onto Pathology
Following a methodology described earlier (21), the prostate specimen underwent a 3T ex vivo MRI scan. The images were the basis for an accurate segmentation of the prostate (Vitrea, Vital Images, Minnetonka, MN, U.S.) for subsequent 3D-printing of a plastic mold (Dimension Elite 3D, Stratasys, Eden Prairie, MN, U.S.) to support precise sectioning. Following complete fixation, the specimen was placed into the custom-built mold for a second high-resolution specimen MRI. Then, the prostate was gross-sectioned within the mold in 3 mm intervals. Volumetric 3 mm stacks of histology sections were then registered onto ex vivo MRI to allow a consistent registration of the ex vivo MRI to pathology (22) .
Registration of Pathology onto In Vivo T2w PET/MRI
All foci of prostate cancer, including the dominant "index nodule", were outlined by the pathologist on whole mount hematoxylin/eosin slides and registered back into the ex vivo and in by on November 7, 2017 
PET/CT Data Analysis
From mpMRI-defined target and mirrored background VOIs, we calculated the 18 F-choline TBR. Five 18 F-choline PET parameters (SUV max , SUV mean , SUV mean x volume, SUV max TBR, and SUV mean TBR) were determined for further analysis.
Statistics
Analyses were conducted using the R statistical package (23) as described in supplemental methods.
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RESULTS
Patient-based Biopsy Results
Targeted biopsies were obtained from one (n = 20) or two (n = 16) mpMRI identified lesions, with an average of 5.0 ± 3.2 targeted biopsy cores per patient. As shown in the Supplemental Table 1 by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from
We assessed whether the addition of 18 F-choline PET/CT would improve the accuracy of mpMRI for the diagnosis of significant cancer. From the following PET parameters tested (lesion SUV max , SUV mean , SUV mean x lesion volume, SUV max TBR, SUV mean TBR), stepwise regression analysis identified the SUV mean TBR as the most predictive parameter (Supplemental Table   2A Table 1 ]), standard and targeted biopsies were negative, but a prior biopsy had shown low-volume Gleason 3+4 prostate cancer that was confirmed to be 0.14 cm 3 on wholemount histology. Given the small lesion volume, it was not surprising that neither mpMRI nor 18 F-choline SUV mean TBR were prospectively or retrospectively abnormal at this location.
In another case (ID 10 [Supplemental Table 1 There is now a large body of evidence that transrectal targeted biopsies using MRI-TRUS fusion improves the detection rate of significant prostate cancer compared to standard biopsies (1, 24) . In fact for the detection of significant disease, transrectal MRI-guided biopsies are as accurate as transperineal biopsies (25), which-until recently-was considered the reference standard for prostate biopsy procedures. Both the PI-RADS system and generic Likert scales have shown significant positive correlations between the assigned suspicion score and the probability of clinically significant cancer (12, 13) .
While mpMRI-guided prostate biopsies appear to be a clear improvement over standard biopsies alone, mpMRI has limitations. A recent study of 235 consecutive patients who underwent mpMRI at 3T with risk-stratification by PI-RADS scoring resulted in an AUC of 0.81 for the detection of clinically significant prostate cancer (26) . Our mpMRI data without 11 C/ 18 F-choline PET are similar to these results. Other recent reports on the detection of significant prostate cancer indicate a high sensitivity, but limited specificity (27, 28) . A larger study including 170 patients undergoing 3T mpMRI with PI-RADS scoring including subsequent pathological proof (based on prostatectomy) resulted in a sensitivity of 77% and a specificity of 68% for TRUS-MRI guided fusion biopsies regarding the detection of significant disease (13) .
Unlike the data supporting the use of mpMRI for clinically-significant prostate cancer detection, the reported performance of 11 C/ 18 F-choline PET for primary prostate cancer has been mixed. Results from earlier studies indicated suitable sensitivity, but limited specificity for the identification of prostate cancer (see review (29)). Since the 11 C/ 18 F-choline uptake of the prostate is often inhomogeneously increased in the central gland, absolute choline uptake measures (SUV mean , SUV max ) can be ambiguous as predictors of pathology, and normalization by a suitable background appears to be beneficial (4). We further attribute possible discrepancies in the identification of primary prostate cancer by 11 C/ 18 F-choline PET in part to uncertainties regarding lesion co-localization on imaging compared to pathology due to the relatively poor spatial resolution of PET (21), expected elevated uptake within benign BPH nodules (29, 30) , and a failure to discriminate between clinically significant vs. insignificant prostate cancer (as recognized in (3-5)). Our exclusion criteria carefully avoided false positive inflammatory lesions (for instance due to a recent prostate biopsy or acute prostatitis (31)). When 11 C-choline PET/CT and MRI have been co-registered with whole mount histology utilizing ex vivo MRI of the prostate specimen, tumor lesions (VOIs) can be defined based on true pathology rather than imaging colocalization (22) . This technique has been used with a previous PET/CT scanner generation (effective axial reconstructed PET image resolution between 8.5 -9 mm), and it was shown that We did not test the predictive value of 18 F-choline PET/CT independently of mpMRI because we were not attempting to supplant mpMRI with PET/CT. Choline PET/CT without mpMRI is often misleading because 18 F-choline uptake can be focally increased in benign tissue, particularly in BPH nodules (3, 29) , which are better characterized on mpMRI (33) . Also, 11 Cand 18 F-choline PET lacks the tissue contrast and spatial resolution typical of mpMRI. In this study, we assessed 18 F-choline PET/CT uptake parameters of mpMRI-identified prostatic lesions; therefore, the highly predictive SUV mean TBR of 18 F-choline was not evaluated as an independent PET parameter, nor was that parameter evaluated prospectively without mpMRI information available. Therefore, the improvement in lesion characterization for the diagnosis of significant prostate cancer can only be expected from a combination of both modalities ( 18 Fcholine PET/MRI). The benefit of hybrid imaging over fusion PET/MRI as done in this study is twofold. First, it eliminates the necessity of additional fusion between methodologies with minor drawbacks described below. Secondly and more importantly, only simultaneous hybrid imaging will permit (cross-modality) parametric PET/MRI imaging (5) on a voxel-by-voxel basis, which may offer further improvements in characterization of small lesions.
One important limitation of this study is related to the uncertainty of the "true" histology of targeted lesions, particularly when resulting as benign or low-grade disease due to targeting errors. Also, mpMRI may have entirely missed an existing cancer, which would have precluded a targeted biopsy of that site. We accounted for these errors -at least in part -by combining targeted and standard biopsies. Nonetheless, we have evidence for both types of error as verified in our small subset of patients undergoing prostatectomy.
Multiple registration tasks were required in this study, each of which has task-specific uncertainties. The first registration task (registration of PET onto T2w MRI) was generally performed without difficulties using rigid registration and additional deformable registration when needed. This registration method is clinically applied and well validated for radiation treatment planning of prostate cancer (34) . The second registration of the T2w MR (including embedded target information) onto real-time TRUS is more difficult and dependent on many factors such as configuration and size of the prostate gland and patient cooperation. Given that the ultrasound system used in this study required multi-point registration (instead of boundary-based registration), visibility of intraprostatic features on both ultrasound and MRI was key for successful registration. The accuracy of the TRUS-MRI fusion could therefore only be assessed visually. Despite these issues, our data as well as other studies have shown substantial improvement in the identification of significant prostate cancer by targeted prostate biopsies using TRUS-MRI fusion. The third registration task -the registration of a stacked whole-mount histology volume onto co-registered PET/MR using ex vivo prostate MRI -has been previously described (21) .
This method verified detection of significant cancers missed on targeted biopsy and it uncovered limitations of imaging to detect significant prostate cancer with unfavorable imaging characteristics.
CONCLUSION
Fusion PET/MRI-TRUS image registration for targeted prostate biopsies is clinically feasible, accurate, and improves identification of clinically significant prostate cancer over mpMRI alone. If the SUV mean TBR threshold of 1.58 we found in this study is verified in an independent patient population, a combination of mpMRI and 18 F-choline PET may be able to challenge the current clinical diagnostic strategy.
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